These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 28134764)
1. The Pleiotropic Role of L1CAM in Tumor Vasculature. Angiolini F; Cavallaro U Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134764 [TBL] [Abstract][Full Text] [Related]
2. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies. Maes H; Olmeda D; Soengas MS; Agostinis P FEBS J; 2016 Jan; 283(1):25-38. PubMed ID: 26443003 [TBL] [Abstract][Full Text] [Related]
3. A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. Angiolini F; Belloni E; Giordano M; Campioni M; Forneris F; Paronetto MP; Lupia M; Brandas C; Pradella D; Di Matteo A; Giampietro C; Jodice G; Luise C; Bertalot G; Freddi S; Malinverno M; Irimia M; Moulton JD; Summerton J; Chiapparino A; Ghilardi C; Giavazzi R; Nyqvist D; Gabellini D; Dejana E; Cavallaro U; Ghigna C Elife; 2019 Mar; 8():. PubMed ID: 30829570 [TBL] [Abstract][Full Text] [Related]
4. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. De Bock K; Cauwenberghs S; Carmeliet P Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363 [TBL] [Abstract][Full Text] [Related]
5. L1CAM in human cancer. Altevogt P; Doberstein K; Fogel M Int J Cancer; 2016 Apr; 138(7):1565-76. PubMed ID: 26111503 [TBL] [Abstract][Full Text] [Related]
6. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Zhao Y; Adjei AA Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391 [TBL] [Abstract][Full Text] [Related]
7. Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives. Shang B; Cao Z; Zhou Q Front Med; 2012 Mar; 6(1):67-78. PubMed ID: 22460450 [TBL] [Abstract][Full Text] [Related]
8. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562 [TBL] [Abstract][Full Text] [Related]
9. Off-tumor target--beneficial site for antiangiogenic cancer therapy? Cao Y Nat Rev Clin Oncol; 2010 Oct; 7(10):604-8. PubMed ID: 20683436 [TBL] [Abstract][Full Text] [Related]
10. L1 cell adhesion molecule as a therapeutic target in cancer. Yu X; Yang F; Fu DL; Jin C Expert Rev Anticancer Ther; 2016; 16(3):359-71. PubMed ID: 26781307 [TBL] [Abstract][Full Text] [Related]
11. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Pradeep CR; Sunila ES; Kuttan G Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508 [TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy: a novel approach to overcome tumor hypoxia. Peng F; Chen M Chin J Cancer; 2010 Aug; 29(8):715-20. PubMed ID: 20663317 [TBL] [Abstract][Full Text] [Related]
13. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Jain RK Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032 [TBL] [Abstract][Full Text] [Related]
14. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Viallard C; Larrivée B Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302 [TBL] [Abstract][Full Text] [Related]
15. Normalization of the vasculature for treatment of cancer and other diseases. Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796 [TBL] [Abstract][Full Text] [Related]